## Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-47. (Canceled).
- 48. (Currently Amended) A pharmaceutical composition for the treatment of allergic rhinitis or urticaria which comprises from about 0.1 mg to 5 mg of descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof, an amount of a decongestant, and a pharmaceutically acceptable carrier.
  - 49-51. (Canceled).
- 52. (Previously presented) The pharmaceutical composition of claim 48 wherein said composition is adapted for oral delivery.
  - 53. (Canceled).
- 54. (Currently amended) A <u>The</u> pharmaceutical composition <u>of claim 48</u>, which <u>further</u> comprises <del>from about 0.1 mg to 5 mg of descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof,</del> pseudoephedrine, and a pharmaceutically acceptable carrier.
  - 55-60. (Canceled).
- 61. (Currently amended) The pharmaceutical composition of claim 54, <del>55, 56, 57, 58 or 59</del> wherein said composition is adapted for oral delivery.
  - 62-68. (Canceled).
- 69. (New) The pharmaceutical composition of claim 48, wherein the amount of descarboethoxyloratadine is about 5 mg.

- 70. (New) The pharmaceutical composition of claim 48, which is adapted for administration in a single dose per day.
- 71. (New) The pharmaceutical composition of claim 52 or 61, which is in the form of capsule or tablet.

3 DCJD: 503794.1